American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33.https://doi.org/10.2337/dc21-S002.
Group TS, Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385(5):416–26. https://doi.org/10.1056/NEJMoa2100165.
Ordovas JM. Genetic links between diabetes mellitus and coronary atherosclerosis. Curr Atheroscler Rep. 2007;9(3):204–10. https://doi.org/10.1007/s11883-007-0020-9.
Article CAS PubMed Google Scholar
Ross S, Gerstein H, Pare G. The genetic link between diabetes and atherosclerosis. Can J Cardiol. 2018;34(5):565–74. https://doi.org/10.1016/j.cjca.2018.01.016.
La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol. 2019;26(2 suppl):15–24. https://doi.org/10.1177/2047487319878373.
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–502. https://doi.org/10.1161/CIRCULATIONAHA.116.022194.
Article CAS PubMed PubMed Central Google Scholar
Liu Z, Ma X, Ilyas I, Zheng X, Luo S, Little PJ, et al. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics. 2021;11(9):4502–15. https://doi.org/10.7150/thno.54498.
Article CAS PubMed PubMed Central Google Scholar
Chang W, Zhu F, Zheng H, Zhou Z, Miao P, Zhao L, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: an implication in the treatment of atherosclerosis. Mol Immunol. 2019;116:73–9. https://doi.org/10.1016/j.molimm.2019.09.021.
Article CAS PubMed Google Scholar
D’Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54:101337. https://doi.org/10.1016/j.molmet.2021.101337.
Article CAS PubMed PubMed Central Google Scholar
Kang Y, Zhan F, He M, Liu Z, Song X. Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis. Vascul Pharmacol. 2020;133–134:106779. https://doi.org/10.1016/j.vph.2020.106779.
Article CAS PubMed Google Scholar
Ganbaatar B, Fukuda D, Shinohara M, Yagi S, Kusunose K, Yamada H, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020;875:173040. https://doi.org/10.1016/j.ejphar.2020.173040.
Article CAS PubMed Google Scholar
Liu Y, Xu J, Wu M, Xu B, Kang L. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. Lipids Health Dis. 2021;20(1):5. https://doi.org/10.1186/s12944-021-01430-y.
Article CAS PubMed PubMed Central Google Scholar
Chen YC, Jandeleit-Dahm K, Peter K. Sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced atherosclerotic plaque instability. J Am Heart Assoc. 2022;11(1):e022761. https://doi.org/10.1161/JAHA.121.022761.
Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73(3):924–67. https://doi.org/10.1124/pharmrev.120.000096.
Article CAS PubMed Google Scholar
Kruger-Genge A, Blocki A, Franke RP, Jung F. Vascular endothelial cell biology: an update. Int J Mol Sci. 2019;20(18).https://doi.org/10.3390/ijms20184411
Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM, Group DER. Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC study. Diabetes Care. 2019;42(7):1284–9. https://doi.org/10.2337/dc18-1613.
Article CAS PubMed PubMed Central Google Scholar
Rossello X, Raposeiras-Roubin S, Oliva B, Sanchez-Cabo F, Garcia-Ruiz JM, Caimari F, et al. Glycated hemoglobin and subclinical atherosclerosis in people without diabetes. J Am Coll Cardiol. 2021;77(22):2777–91. https://doi.org/10.1016/j.jacc.2021.03.335.
Rooney MR, Tang O, Pankow JS, Selvin E. Glycaemic markers and all-cause mortality in older adults with and without diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetologia. 2021;64(2):339–48. https://doi.org/10.1007/s00125-020-05285-3.
Article CAS PubMed Google Scholar
Clyne AM. Endothelial response to glucose: dysfunction, metabolism, and transport. Biochem Soc Trans. 2021;49(1):313–25. https://doi.org/10.1042/BST20200611.
Article CAS PubMed PubMed Central Google Scholar
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377–90. https://doi.org/10.1038/s41581-020-0278-5.
Article PubMed PubMed Central Google Scholar
Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules. 2022;12(4).https://doi.org/10.3390/biom12040542.
Indyk D, Bronowicka-Szydelko A, Gamian A, Kuzan A. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. Sci Rep. 2021;11(1):13264. https://doi.org/10.1038/s41598-021-92630-0.
Article CAS PubMed PubMed Central Google Scholar
Banarjee R, Sharma A, Bai S, Deshmukh A, Kulkarni M. Proteomic study of endothelial dysfunction induced by AGEs and its possible role in diabetic cardiovascular complications. J Proteomics. 2018;187:69–79. https://doi.org/10.1016/j.jprot.2018.06.009.
Article CAS PubMed Google Scholar
Catan A, Turpin C, Diotel N, Patche J, Guerin-Dubourg A, Debussche X, et al. Aging and glycation promote erythrocyte phagocytosis by human endothelial cells: potential impact in atherothrombosis under diabetic conditions. Atherosclerosis. 2019;291:87–98. https://doi.org/10.1016/j.atherosclerosis.2019.10.015.
Article CAS PubMed Google Scholar
Tsukahara R, Haniu H, Matsuda Y, Tsukahara T. The AGP-PPARgamma axis promotes oxidative stress and diabetic endothelial cell dysfunction. Mol Cell Endocrinol. 2018;473:100–13. https://doi.org/10.1016/j.mce.2018.01.008.
Article CAS PubMed Google Scholar
Deng X, Huang W, Peng J, Zhu TT, Sun XL, Zhou XY, et al. Irisin alleviates advanced glycation end products-induced inflammation and endothelial dysfunction via inhibiting ROS-NLRP3 inflammasome signaling. Inflammation. 2018;41(1):260–75. https://doi.org/10.1007/s10753-017-0685-3.
Article CAS PubMed Google Scholar
Ren X, Ren L, Wei Q, Shao H, Chen L, Liu N. Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol. 2017;16(1):52. https://doi.org/10.1186/s12933-017-0531-9.
Article CAS PubMed PubMed Central Google Scholar
Rajaraman B, Ramadas N, Krishnasamy S, Ravi V, Pathak A, Devasena CS, et al. Hyperglycaemia cause vascular inflammation through advanced glycation end products/early growth response-1 axis in gestational diabetes mellitus. Mol Cell Biochem. 2019;456(1–2):179–90. https://doi.org/10.1007/s11010-019-03503-0.
Article CAS PubMed Google Scholar
Ninomiya H, Katakami N, Sato I, Osawa S, Yamamoto Y, Takahara M, et al. Association between subclinical atherosclerosis markers and the level of accumulated advanced glycation end-products in the skin of patients with diabetes. J Atheroscler Thromb. 2018;25(12):1274–84. https://doi.org/10.5551/jat.44859.
Article CAS PubMed PubMed Central Google Scholar
Do MH, Lee JH, Ahn J, Hong MJ, Kim J, Kim SY. Isosamidin from Peucedanum japonicum roots prevents methylglyoxal-induced glucotoxicity in human umbilical vein endothelial cells via suppression of ROS-mediated Bax/Bcl-2. Antioxidants (Basel). 2020;9(6).https://doi.org/10.3390/antiox9060531.
Johnson LL, Johnson J, Ober R, Holland A, Zhang G, Backer M, et al. Novel receptor for advanced glycation end products-blocking antibody to treat diabetic peripheral artery disease. J Am Heart Assoc. 2021;10(1):e016696. https://doi.org/10.1161/JAHA.120.016696.
Article CAS PubMed Google Scholar
Shao M, Yu M, Zhao J, Mei J, Pan Y, Zhang J, et al. miR-21-3p regulates AGE/RAGE signalling and improves diabetic atherosclerosis. Cell Biochem Funct. 2020;38(7):965–75. https://doi.org/10.1002/cbf.3523.
Article CAS PubMed Google Scholar
Barbu E, Popescu MR, Popescu AC, Balanescu SM. Inflammation as a precursor of atherothrombosis, diabetes and early vascular aging. Int J Mol Sci. 2022;23(2).https://doi.org/10.3390/ijms23020963.
Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol (Lausanne). 2012;3:181. https://doi.org/10.3389/fendo.2012.00181.
Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018;122(12):1722–40. https://doi.org/10.1161/CIRCRESAHA.118.311362.
Article CAS PubMed Google Scholar
Boni-Schnetzler M, Meier DT. Islet inflammation in type 2 diabetes. Semin Immunopathol. 2019;41(4):501–13. https://doi.org/1
留言 (0)